Clinical Trial News and Research

RSS

Neovasc's 2009 revenues up 94%

Neovasc Inc., today announced financial results for the year ended December 31, 2009.

13 Apr 2010

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.

13 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

Copaxone achieves one million patient years of experience in treatment of RRMS

Teva Pharmaceutical Industries, Ltd. announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA).

13 Apr 2010

Cancer drug, antiviral agent can eradicate active virus infection and tumor: UNC School of Medicine

Important advances in the fight against cancer have come as researchers proved that viruses and cancers interact in ways that were previously unknown to scientists.

13 Apr 2010

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Myriad Pharmaceuticals, Inc today announced that it has received a notice from Javelin Pharmaceuticals, Inc. of its intent to terminate the merger agreement between the two companies.

13 Apr 2010

Vitamins touted in skin care products reduce signs of sun-damaged skin: Study

While everyone knows that getting an adequate daily dose of vitamins and minerals is important in maintaining one's overall health, many question whether or not the vitamins touted in skin care products work in reducing the signs of sun-damaged skin.

13 Apr 2010

Common drug used to treat Burkitt lymphoma can activate EBV: Study

Important advances in the fight against cancer have come as researchers proved that viruses and cancers interact in ways that were previously unknown to scientists.

13 Apr 2010

Research on efficacy of yoga in breast cancer treatment attracts award of over $4.5M

In an ongoing effort to scientifically validate the age-old belief that mind-body interventions have a beneficial impact on the health of patients, The University of Texas M. D. Anderson Cancer Center has been awarded more than $4.5 million to study the efficacy of incorporating yoga into the treatment program of women with breast cancer.

13 Apr 2010

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

13 Apr 2010

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences, Inc. today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.

13 Apr 2010

Researchers evaluate new treatment for coronary heart disease

Some patients with heart muscles seriously affected by coronary heart disease may soon be able to benefit from an innovative treatment.

13 Apr 2010

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. "We have accomplished a great deal of work for a small company on a very tight budget. We have GMP drug ready for the Phase I clinical trial and the Phase I site is prepared to begin this protocol," said Dr. Donald Picker , the company CEO.

12 Apr 2010

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Inhibitex, Inc. today announced that the independent Data Safety Monitoring Board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with 30-day follow-up data on the first half of the patients that the Company plans to enroll in the trial.

12 Apr 2010

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

GenVec, Inc. announced that encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium -- Malaria: New Approaches to Understanding Host-Parasite Interactions taking place April 11-16, 2010 in Copper Mountain, Colorado.

12 Apr 2010

BioClinica to showcase expanded suite of services at upcoming global industry conferences

BioClinica, Inc., a leading provider of clinical trial management services will participate in, and present at, key industry conferences during April and May. Principal members of the BioClinica team will participate as expert panelists as well as demonstrate the value of the Company's expanded suite of services at these conferences.

From Clario 12 Apr 2010

Internet-based CBT as effective as group therapy for treating panic disorder

Cognitive behaviour therapy (CBT) via the internet is just as effective in treating panic disorder (recurring panic attacks) as traditional group-based CBT. It is also efficacious in the treatment of mild and moderate depression. This according to a new doctoral thesis soon to be presented at the Swedish medical university Karolinska Institutet.

12 Apr 2010

Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin

Optimer Pharmaceuticals, Inc. announced that the top-line results from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection were presented today at the 20th Annual European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria.

12 Apr 2010

U-M Medical School researchers earn $366M in NIH research funding in fiscal year 2009

University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.

12 Apr 2010

New TIVR telephone system to teach pain management skills to patients with arthritis

Joan Broderick, Ph.D., Research Associate Professor, Department of Psychiatry and Behavioral Sciences at Stony Brook University, has received a $606,000 grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.

12 Apr 2010

Clinical Trial News and Research

Neovasc's 2009 revenues up 94%

EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Copaxone achieves one million patient years of experience in treatment of RRMS

Cancer drug, antiviral agent can eradicate active virus infection and tumor: UNC School of Medicine

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Vitamins touted in skin care products reduce signs of sun-damaged skin: Study

Common drug used to treat Burkitt lymphoma can activate EBV: Study

Research on efficacy of yoga in breast cancer treatment attracts award of over $4.5M

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Gilead Sciences doses first patient in Quad Phase III clinical program

Researchers evaluate new treatment for coronary heart disease

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

BioClinica to showcase expanded suite of services at upcoming global industry conferences

Internet-based CBT as effective as group therapy for treating panic disorder

Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin

U-M Medical School researchers earn $366M in NIH research funding in fiscal year 2009

New TIVR telephone system to teach pain management skills to patients with arthritis

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer